Algorae Pharmaceuticals Limited · ASX:1AI
Algorae Pharmaceuticals — Non-Deal Roadshow (February 2026)
19 slides from Algorae Pharmaceuticals's roadshow presentation, February 2026
Slide 1: A healthier future
Accessible care Advanced science A healthier future ASX:1AI (Non-deal Presentation Feb 2026)
Slide 2: Disclaimer: Important Information
Disclaimer: Important Infor mation Non-deal Presentation (February 2026) Not an offer of Securities. This document has been independently prepared by Algorae Pharmaceuticals Ltd (Algorae) and is provided for informational purposes only. This document does not constitute or contain an offer, invitati
Slide 3: Algorae is an ASX listed company, with two pillars aligned to a single focus
Algorae is an ASX listed company, with two pillars aligned to a single focus. Delivering safe, accessible, innovative medicines to improve every life. ASX Code 1AI Top 40 : 61% Shares on issue 1.68bn Share price* $0.02 Market cap $33.7m 2,856 Management : 6% SHAREHOLDERS Cash** $1.8m Other : 33% EV
Slide 4: Australian Pharmaceutical Market
Australian Pharmaceutical Market The Australian pharmaceutical market was valued at $24 Billion in 2025 and is expected to reach $34 Billion by 2030. Supply is dominated by internationally headquartered pharmaceutical companies. In January 2026 there were 420 medication shortages registered with the
Slide 5: Policy Reform in Australia – Growth Driver
Policy Refor m in Australia – Growth Driver Government reforms are lowering out-of-pocket costs and expanding primary-care access, and these are expected to support higher medicine utilisation, a structural tailwind for generics. PBS Reforms General co-payment: $42.50 → $30 (1 Jan 23) → indexed to $
Slide 6: Population Ageing – Growth Driver
Population Ageing – Growth Driver Population ageing has been a key structural driver of health spending over the next 40 years. The 65+ cohort is the fastest-growing segment, rising from 17% to 27% of the population by 2071. Older Australians (60+) account for around 63% of PBS prescriptions and 60%
Slide 7: Product Innovation – Growth Driver
Product Innovation – Growth Driver Product innovation leads to new clinical and distribution markets in the Australian pharmaceutical sector Product Innovation: Patents New drug discoveries New drug / device combinations New drug combinations Product Innovation: Specialty & Generic Enhanced product
Slide 8: AlgoraeRx: Pharmaceutical Commercial; Research & Development
AlgoraeRx: Pharmaceutical Commercial Our ANZ commercial division: sourcing, licensing and supplying generic and specialty medicines. Focus: convert supply & licensing opportunities into near term revenue growth in Australia and New Zealand. Research & Development AlgoraeOS is our AI-powered drug dis
Slide 9: Executive team combines medication supply-chain, pharmacy services and capital markets experience
Collectively, the executive team combines deep medication supply-chain, pharmacy services and capital markets experience. Board of Directors Mr. David Hainsworth Mr. Brad Latham Mr. Brad Dilkes Executive Chairman Non-Executive Director Non-Executive Director 25+ years in capital markets 20+ years of
Slide 10: Pharmaceutical Commercial AlgoraeRx
Pharmaceutical Commercial AlgoraeRx 9
Slide 11: AlgoraeRx Strategic Expansion
AlgoraeRx Our commercial division targeting the supply of generic and specialised medicines in ANZ Strategic Expansion Addressing significant unmet local medical and clinical supply needs Unlocking high-value commercial revenue opportunities in underserved market segments Strategically positioned to
Slide 12: Proven In-Market Execution
Proven In-Market Execution Proven execution across sourcing, licensing and commercialisation underpins our in-market capability Execution Access Networks 40+ years pharma expertise in Deep expertise in supply chain, Established relationships with operations, sales, marketing, BD&L compounding, distr
Slide 13: Partner Contracts Executed
Partner Contracts Executed Executed contracts with leading global manufacturers are accelerating our revenue pipeline, with further partnerships under active negotiation. Partner Contract Type Number of Products SAKAR Licensing / Registration 5 CADILA Licensing / Registration 2 DR REDDYS Distributio
Slide 14: Research & Development
Research & Development 13
Slide 15: Core Scientific Team
Core Scientific Team Dr. James McKenna Prof. Kaylene Simpson Chief Scientific Officer AI Validation Testing Algorae Pharmaceuticals PMCC / VCFG Leads high throughput screening at Peter Mac for the AI validation testing A/Prof Fatemeh Vafaee Dr. Muhammad Heydari Artificial Intelligence Artificial Int
Slide 16: R&D AlgoraeOS
R&D AlgoraeOS Research Partners AlgoraeOS is our AI-powered discovery engine that generates a pipeline of drug-combination leads for internal development or partnering. We combine in-silico prediction with wet-lab validation to prioritise high-confidence candidates for licensing or co-development. D
Slide 17: R&D AlgoraeOS
R&D AlgoraeOS Independent validation de-risks AlgoraeOS prediction engine; v2 scales pipeline generation Independent preclinical validation (Peter Mac / VCFG) 21 drug-CBD targets tested across 4 cancer cell lines (~10,000 datapoints generated) AOS1 differentiated synergistic vs non-synergistic pairs
Slide 18: R&D Preclinical Pipeline
R&D Preclinical Pipeline AI-116: fixed-dose combination target (Dementia) Program: fixed-dose combination (Donepezil + CBD) for dementia Preclinical signal: 53% cell viability vs 17% with donepezil alone (in vitro model) Rationale: targets neuroinflammation, oxidative stress and excitotoxicity pathw
Slide 19: Corporate & Media Inquiries
Corporate & Media Inquiries investors@algoraepharma.com Corporate Address Level 23, Rialto South Tower 525 Collins St Melbourne VIC 3000 18
Algorae Pharmaceuticals — Non-Deal Roadshow (February 2026) on 6ix